5th Annual Revolutionizing Atopic Dermatitis (RAD) Conference - April 29-May 1, 2023 - Virtual
Although diagnosis of Atopic Dermatitis (AD) is straightforward in children, its diagnosis is challenging in adults. Advances in research on AD epidemiology, burden and comorbidities have transformed the understanding of the course of AD, including risk factors, age of onset, disease severity and persistence, and health outcomes. Clinicians may not be aware of the epidemiology of AD for proper risk stratification, patient education and therapeutic decision-making. Atopic dermatitis is a heterogeneous disorder with variable severity of signs and symptoms, and impact on quality of life. Clinicians may not be able to assess AD severity accurately in order to optimize therapy. Our Conference allows clinicians to understand this disease better through the latest in research, expert faculty speakers, late-breaking research and Q&A sessions.
Registration Rates - Virtual Conference
Group |
Early-Bird Rates
|
March 1-April 14, 2023 |
April 15, 2023-
|
Physicians |
$150 |
$250 |
$350 |
RNs, NPs, APRNs, PAs | $75 | $125 | $175 |
Residents and Fellows | $50 | $75 | $100 |
Industry - Exhibits and Scientific Sessions | $300 | $450 | $700 |
Students | $15 | $35 | $50 |
Patients | Free | Free | Free |
Media | $150 | $250 | $350 |
If you are a patient, caregiver, student or member of the media, and you are interested in attending the Conference, please contact Patrice Melluso: patrice@revolutionizingad.com
If you registered for the program and did not receive your registration confirmation email, please check your spam/junk folder. If you are unable to find the email, please email Donna Jimenez: djimenez@dnadigitalgroup.com
Target Audience
This program is intended for dermatologists, allergists and immunologists, primary care clinicians, NPs/RNs/APRNs, physician assistants and other allied health professionals as well as patients/patient groups engaged in the care of patients with Atopic Dermatitis (AD).
Educational Objectives
After completing this activity, the participant should be better able to:
- Discuss improved understanding of pathophysiology, disease course and current, available treatment options in therapeutic decision making for atopic dermatitis and related comorbidities
- Apply principals of long-term management to tailor and optimize therapy for patients
- Identify best-practice in therapeutics for atopic dermatitis
- Incorporate new and emerging therapeutics into the management of atopic dermatitis
- Relate racial and healthcare disparities and identify strategies to reduce disparities in atopic dermatitis
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Revolutionizing Atopic Dermatitis. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this live activity for a maximum 13.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 13.00 contact hours.
CONTINUING PHYSICIAN ASSISTANT EDUCATION
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.